NSABP Members' Area
Password Protected - Access
Limited to NSABP Participating
Institutions Only
NSABP Foundation, Inc.
General NSABP Information
Financial Conflicts of
Interest Policy
Contact the NSABP
Employment
Clinical Trials Information
Clinical Trials Overview
Protocol Chart
Never Say Lost
Treatment Trials Information
Protocol B-51
Protocol B-52
Protocol B-53/S1207
Protocol B-55/BIG 6-13
Prevention Trials Information
Protocol P-1 - BCPT
Protocol P-2 - STAR
To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu
Protocol B-15
A Three-Arm Clinical Trial Comparing Short, Intensive Adriamycin-Cyclophosphamide Chemotherapy With and Without Interval Reinduction Chemotherapy (CMF) to "Conventional" CMF in Positive-Node Patients Having The Following Age and Receptor Criteria:
49 Years or younger - All Patients
50-59 Years - PR<10 fmol, regardless of ER
Specific Aims
To determine, in patients with histologically positive axillary nodes who are not classified as tamoxifen-responsive, whether short, intensive adjuvant chemotherapy (AC, with or without interval reinduction with CMF) is as effective as or more effective than "conventional" CMF with respect to disease-free survival and survival.
